摘要:
Compounds of formula (I), and salts and prodrugs thereof, wherein Q represents optionally substituted phenyl, naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or indazolyl; Z represents O, S or NR.sup.8 ; X and Y are H or are together .dbd.O; R.sup.1 and R.sup.2 are H; optionally substituted C.sub.1-6 alkyl; optionally substituted phenyl(C.sub.1-4 alkyl); COR.sup.c ; CO.sub.2 R.sup.c ; CONR.sup.c R.sup.d ; CONR.sup.c COOR.sup.d ; or SO.sub.2 R.sup.c ; R.sup.3 is H or C.sub.1-6 alkyl, R.sup.4 is H , C.sub.1-6 alkyl or optionally substituted phenyl; and R.sup.5 represents optionally substituted phenyl; are tachykinin antagonists. They and compositions thereof are useful in therapy.
摘要:
The present invention relates to compounds of formula (I), wherein R.sup.1 is hydrogen, halogen, C.sub.1-6 C alkyl, C.sub.1-6 alkoxy, CF.sub.3, NO.sub.2, CN, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, CO.sub.2 R.sup.a, CONR.sup.a R.sup.b, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or C.sub.1-4 alkyl substituted by C.sub.1-4 alkoxy, where R.sup.a and R.sup.b are hydrogen or C.sub.1-4 alkyl; R.sup.2 is hydrogen, halogen, C .sub.1-6 alkyl, C.sub.1-6 alkoxy substituted by C.sub.1-4 alkoxy or CF.sub.3 ; R.sup.3 is hydrogen, halogen or CF.sub.3 ; R.sup.4 is selected from the definitions of R.sup.1 ; R.sup.5 is selected from the definitions of R.sup.2 ; R.sup.6 is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by .dbd.O, .dbd.S or a C.sub.1-4 alkyl group, and optionally substituted by an aminoalkyl group; R.sup.9a and R.sup.9b are hydrogen or C.sub.1-4 alkyl, or R.sup.9a and R.sup.9b are joined to form a C.sub.5-7 ring; X is C.sub.1-4 alkylene optionally substituted by oxo; and Y is a C.sub.1-4 alkyl group optionally substituted by hydroxyl; with the proviso that if Y is C.sub.1-4 alkyl, R.sup.6 is substituted at least by an aminoalkyl group; and pharmaceutically acceptable salts and prodrugs thereof. The compounds are of particular use in the treatment of pain, inflammation, migraine and emesis.
摘要:
Novel .alpha.-hydroxyphosphonate compounds which inhibit mammalian phosphoinositide-specific phospholipase-C. The compounds are potent anti-inflammatory and analgesic agents and may be useful for the treatment of cancer.
摘要:
Compounds of formula (I), and salts and prodrugs thereof, wherein Q.sup.1 is phenyl substituted by one or more halo; optionally substituted naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or fluorenyl; the dotted line represents an optional covalent bond; one of X and Y is H and the other is hydroxy or C.sub.1-6 alkoxy, or X and Y together form a group .dbd.O or .dbd.NOR.sup.5 where R.sup.5 is H or C.sub.1-6 alkyl; R.sup.1 is H or C.sub.1-6 alkyl. R.sup.2 is CO--W--R.sup.6 where W represents a bond or a hydrocarbon chain of 1-6 carbon atoms and R.sup.6 is an azacyclic or azabicyclic group; R.sup.3 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; and R.sup.4 is phenyl optionally substituted by 1-3 of C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR.sup.a, SR.sup.a, SOR.sup.a, NR.sup.a R.sup.b, NR.sup.a COR.sup.b, NR.sup.a CO.sub.2 R.sup.b, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b, where R.sup.a and R.sup.b are H, C.sub.1-6 alkyl, phenyl or trifluoromethyl; are tachykinin antagonists useful in therapy.
摘要翻译:PCT No.PCT / GB93 / 01415 Sec。 371日期1995年1月13日 102(e)日期1995年1月13日PCT提交1993年7月6日PCT公布。 出版物WO94 / 01402 日期:1994年1月20日式(I)化合物及其盐和前药其中Q1是被一个或多个卤素取代的苯基; 任选取代的萘基,吲哚基,苯并噻吩基,苯并呋喃基,苄基或芴基; 虚线表示任选的共价键; X和Y之一是H,另一个是羟基或C 1-6烷氧基,或X和Y一起形成基团= O或= NOR 5,其中R 5是H或C 1-6烷基; R1是H或C1-6烷基。 R2是CO-W-R6,其中W表示1-6个碳原子的键或烃链,R6是氮杂环或氮杂双环基; R3是H,C1-6烷基或C2-6烯基; R4是任选被1-3个C 1-6烷基,C 2-6烯基,C 2-6炔基,卤素,氰基,硝基,三氟甲基,三甲基甲硅烷基,OR a,SR a,SOR a,NR a R b,NR a COR b,NR a CO 2 R b,CO 2 R a或CONR a R b, 其中R a和R b是H,C 1-6烷基,苯基或三氟甲基; 是用于治疗的速激肽拮抗剂。
摘要:
Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein Q.sup.1 is halo substituted phenyl; naphthyl; indolyl; benzthiophenyl; benzofuranyl; benzyl; or fluorenyl; . . is an optional covalent bond;one of X and Y is H and the other is hydroxy or C.sub.1-6 alkoxy, or X and Y are together .dbd.0 or .dbd.NOR.sup.5 ;R.sup.1 and R.sup.2 are H; C.sub.1-6 alkyl optionally substituted by hydroxy, cyano, COR.sup.c, CO.sub.2 R.sup.c, CONR.sup.c R.sup.d, or NR.sup.c R.sup.d (where R.sup.c and R.sup.d are H, C.sub.1-6 alkyl or phenyl(C.sub.0-4 alkyl) optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo and trifluoromethyl); phenyl(C.sub.1-4 alkyl) (optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo or trifluoromethyl); COR.sup.c ; CO.sub.2 R.sup.c ; CONR.sup.c R.sup.d ; COC.sub.1-6 alkylNR.sup.c R.sup.d ; CONR.sup.c COOR.sup.d ; or SO.sub.2 R.sup.c ;R.sup.3 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; andR.sup.4 is phenyl optionally substituted by C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR.sup.a, SR.sup.a, SOR.sup.a, NR.sup.a R.sup.b, NR.sup.a COR.sup.b, NR.sup.a CO.sub.2 R.sup.b, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b, where R.sup.a and R.sup.b are H, C.sub.1-6 alkyl, phenyl or trifluoromethyl; are tachykinin antagonists.
摘要翻译:式(I)化合物及其盐和前药其中Q 1是卤素取代的苯基; 萘基; 吲哚基 苯硫酚 苯并呋喃基 苄基; 或芴基; 。 。 。 是可选的共价键; X和Y之一是H,另一个是羟基或C 1-6烷氧基,或X和Y一起= 0或= NOR5; R1和R2是H; 任选被羟基,氰基,CORc,CO2Rc,CONRcRd或NRcRd取代的C 1-6烷基(其中R c和R d为H,任选被C 1-6烷基,C 1-6烷氧基,卤素和三氟甲基取代的C 1-6烷基或苯基(C 0-4烷基) ); 苯基(C 1-4烷基)(任选被C 1-6烷基,C 1-6烷氧基,卤素或三氟甲基取代); CORC; CO2Rc; CONRcRd; COC 1-6烷基NR c R d; CONRcCOORd; 或SO2Rc; R3是H,C1-6烷基或C2-6烯基; R4是任选被C 1-6烷基,C 2-6烯基,C 2-6炔基,卤素,氰基,硝基,三氟甲基,三甲基甲硅烷基,OR a,SR a,SOR a,NR a R b,NR a COR b,NR a CO 2 R b,CO 2 R a或CONR a R b任意取代的苯基,其中R a和R b是 H,C 1-6烷基,苯基或三氟甲基; 速激肽拮抗剂。
摘要:
Compounds of formula (I), wherein Q.sup.1 represents an aryl group; the dotted line represents an optional covalent bond; one of X and Y represents H and the other represents hydroxy or C.sub.1-6 alkoxy, or X and Y together form a group .dbd.O or .dbd.NOR.sup.5 where R.sup.5 is H or C.sub.1-6 alkyl; Z represents O, S or NR.sup.2, where R.sup.2 is H or C.sub.1-6 alkyl; W represents a bond or a saturated or unsaturated hydrocarbon chain of 1, 2, 3, 4, 5 or 6 carbon atoms; R.sup.1 represents H or C.sub.1-6 alkyl. R.sup.3 represents H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; R.sup.4 represents an optionally substituted phenyl group; and R.sup.6 represents a specified amino group or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group; and salts and prodrugs are tachykinin receptor antagonists.
摘要:
Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein Q.sup.1 is halo substituted phenyl; naphthyl; indolyl; benzthiophenyl; benzofuranyl; benzyl; or fluorenyl; . . is an optional covalent bond;one of X and Y is H and the other is hydroxy or C.sub.1-6 alkoxy, or X and Y are together .dbd.O or .dbd.NOR.sup.5 ;R.sup.1 and R.sup.2 are H; C.sub.1-6 alkyl optionally substituted by hydroxy, cyano, COR.sup.c, CO.sub.2 R.sup.c, CONR.sup.c R.sup.d, or NR.sup.c R.sup.d (where R.sup.c and R.sup.d are H, C.sub.1-6 alkyl or phenyl(C.sub.0-4 alkyl) optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo and trifluoromethyl); phenyl(C.sub.1-4 alkyl) (optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo or trifluoromethyl); COR.sup.c ; CO.sub.2 R.sup.c ; CONR.sup.c R.sup.d ; COC.sub.1-6 alkylNR.sup.c R.sup.d ; CONR.sup.c COOR.sup.d ; or SO.sub.2 R.sup.c ;R.sup.3 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; andR.sup.4 is phenyl optionally substituted by C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR.sup.a, SR.sup.a, SOR.sup.a, NR.sup.a R.sup.b, NR.sup.a COR.sup.b, NR.sup.a CO.sub.2 R.sup.b, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b, where R.sup.a and R.sup.b are H, C.sub.1-6 alkyl, phenyl or trifluoromethyl; are tachykinin antagonists.
摘要翻译:式(I)化合物及其盐和前药其中Q 1是卤素取代的苯基; 萘基; 吲哚基 苯硫酚 苯并呋喃基 苄基; 或芴基; 。 。 。 是一个可选的共价键; X和Y之一是H,另一个是羟基或C 1-6烷氧基,或X和Y一起= O或= NOR 5; R1和R2是H; 任选被羟基,氰基,CORc,CO2Rc,CONRcRd或NRcRd取代的C 1-6烷基(其中R c和R d为H,任选被C 1-6烷基,C 1-6烷氧基,卤素和三氟甲基取代的C 1-6烷基或苯基(C 0-4烷基) ); 苯基(C 1-4烷基)(任选被C 1-6烷基,C 1-6烷氧基,卤素或三氟甲基取代); CORC; CO2Rc; CONRcRd; COC 1-6烷基NR c R d; CONRcCOORd; 或SO2Rc; R3是H,C1-6烷基或C2-6烯基; R4是任选被C 1-6烷基,C 2-6烯基,C 2-6炔基,卤素,氰基,硝基,三氟甲基,三甲基甲硅烷基,OR a,SR a,SOR a,NR a R b,NR a COR b,NR a CO 2 R b,CO 2 R a或CONR a R b任意取代的苯基,其中R a和R b是 H,C 1-6烷基,苯基或三氟甲基; 速激肽拮抗剂。
摘要:
A class of novel thiadiazoles, substituted on one of the ring carbon atoms with a non-aromatic azacyclic or azabicyclic ring system, and substituted on the other ring carbon atom with a substituent of low lipophilicity, or a hydrocarbon substituent; are potent muscarinic agonists, and have good CNS penetrability. The compounds are therefore useful in the treatment of neurological and mental illnesses, and are also of benefit in the treatment of severe painful conditions.
摘要:
Compounds of formula (I): ##STR1## wherein Q.sup.1 represents a phenyl group substituted by one or more halo; naphthyl; indolyl; benzthiophenyl; benzofuranyl; benzyl; or fluorenyl;R.sup.1 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl;R.sup.2 is phenyl(C.sub.1-4 alkyl) optionally substituted in the phenyl ring by one or more groups selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, SR.sup.b, SOR.sup.b, SO.sub.2 R.sup.b, OR.sup.b, NR.sup.b R.sup.c, NR.sup.b COR.sup.c, NR.sup.b COOR.sup.c, COOR.sup.b or CONR.sup.b R.sup.c, where R.sup.b and R.sup.c independently represent H, C.sub.1-6 alkyl, phenyl or trifluoromethyl; andZ is O, S, NR.sup.8 or CR.sup.9 R.sup.10, where R.sup.8 represents H C.sub.1-6 alkyl, phenyl, phenyl(C.sub.1-4 alkyl), COR.sup.11, COOR.sup.11, CONR.sup.9 R.sup.10 where R.sup.11 is phenyl, phenyl(C.sub.1-4 alkyl) or C.sub.1-6 alkyl, and R.sup.9 and R.sup.10 are each H, C.sub.1-6 alkyl, phenyl or phenyl(C.sub.1-4 alkyl); are tachykinin antagonists. They and their compositions are useful in medicine.
摘要翻译:式(I)的化合物:其中Q1表示被一个或多个卤素取代的苯基; 萘基; 吲哚基 苯硫酚 苯并呋喃基 苄基; 或芴基; R1是H,C1-6烷基或C2-6烯基; R2是在苯环中被选自C 1-6烷基,C 2-6烯基,C 2-6炔基,卤素,氰基,硝基,三氟甲基,SR b,SOR b,SO 2 R b,OR b,NR b R c中的一个或多个基团任意取代的苯基(C 1-4烷基) NRbCORc,NRbCOORc,COORb或CONRbRc,其中Rb和Rc独立地表示H,C1-6烷基,苯基或三氟甲基; 并且Z是O,S,NR8或CR9R10,其中R8代表H C1-6烷基,苯基,苯基(C1-4烷基),COR11,COOR11,CONR9R10,其中R11是苯基,苯基(C1-4烷基)或C1-6烷基,和 R 9和R 10各自为H,C 1-6烷基,苯基或苯基(C 1-4烷基); 速激肽拮抗剂。 它们及其组合物在医学中是有用的。
摘要:
The present invention is directed to compounds of the formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are defined herein, and pharmaceutically acceptable salts thereof, which are useful as tachykinin antagonists,